FDA Treads Carefully On Reprints, Citing Taxotere “Carrier,” Not Study
Executive Summary
Printing a list of "unsubstantiated" superiority claims for breast cancer drug Taxotere (docetaxel) on the outside of study reprints has earned Sanofi Aventis a citation letter from FDA's Division of Drug Marketing, Advertising and Communications